Effective delivery of mRNA or small molecule drugs to the brain is a significant challenge in
developing treatment for acute ischemic stroke (AIS). To address the problem, we have …

After more than 100 failed drug trials for acute ischemic stroke (AIS), one of the most
commonly cited reasons for the failure has been that drugs achieve very low concentrations …

Ischemic stroke is a deadly vascular central nervous system disease that causes disability
and death worldwide. 1 Enzymatic thrombolysis and mechanical thrombectomy are the main …

Lipid nanoparticles (LNPs) hold great promise as carriers for developing drug delivery
systems (DDSs) aimed at managing ischemic stroke (IS). Previous research has highlighted …

Haemorrhagic stroke represents a significant public health burden, yet our knowledge and
ability to treat this type of stroke are lacking. Previously we showed that we can target …

Drug targeting to inflammatory brain pathologies such as stroke and traumatic brain injury
remains an elusive goal. Using a mouse model of acute brain inflammation induced by local …

Ischemic stroke is still one of the leading causes of high mortality and severe disability
worldwide. Therapeutic options for ischemic stroke and subsequent cerebral …

Current treatments for ischemic stroke are insufficient. The lack of effective pharmacological
approaches can be mainly attributed to the difficulty in overcoming the blood–brain barrier …

The development of effective therapies for stroke continues to face repeated translational
failures. Brain endothelial cells form paracellular and transcellular barriers to many blood …

The translation of experimental stroke research from the laboratory to successful clinical
practice remains a formidable challenge. We previously reported that PEGylated-lipid …